Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
Solid pharmaceutical formulation for a sustained pH-independent active ingredient release comprising at least one layer of one or more water-insoluble polymers, at least one layer of one or more pH-dependently water-soluble polymers and an active ingredient-containing core, having strong pH-dependent water solubility and comprises at least one osmagent.
1 . Solid pharmaceutical formulation for a sustained pH-independent active ingredient release comprising
at least one layer of one or more water-insoluble polymers
at least one layer of one or more pH-dependent water-soluble polymers, and
an active ingredient-containing core, where
the core comprises an active ingredient having strong pH-dependent water solubility and at least one osmagent.
2 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more pH-dependent water-soluble polymers is the outer layer of the solid pharmaceutical formulation, and the layer of one or more water-insoluble polymers is the inner one.
3 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more water-insoluble polymers is from 1% to 40% w/w based on the total mass of the formulation.
4 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more water-insoluble polymers is from 1% to 10% w/w based on the total mass of the formulation.
5 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more water-insoluble polymers is from 2% to 5% w/w based on the total mass of the formulation.
6 . Solid pharmaceutical formulation according to claim 1 , where one or more water-insoluble polymers from the group comprising polyvinyl acetate, alkylcelluloses, acrylate-methacrylate copolymers, vinyl acetate-methacrylate copolymers and acrylate copolymers, ethylcellulose, ethyl acrylate-methyl methacrylate copolymer and ethyl acrylate-methyl acrylate-trimethylammoniummethyl methacrylate chloride terpolymer and mixtures thereof are selected.
7 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more water-insoluble polymers comprises one or more pore-forming substances.
8 . Solid pharmaceutical formulation according to claim 1 , where the pore-forming substance is selected from the group comprising polyvinyl-pyrrolidone, crospovidone, hydroxypropylmethylcellulose, polyethylene glycol, hydroxypropylcellulose and mixtures thereof.
9 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more pH-dependent water-soluble polymers is from 1% to 40% w/w based on the total mass of the formulation.
10 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more pH-dependent water-soluble polymers is from 1% to 10% w/w based on the total mass of the formulation.
11 . Solid pharmaceutical formulation according to claim 1 , where the layer of one or more pH-dependent water-soluble polymers is from 2% to 5% w/w based on the total mass of the formulation.
12 . Solid pharmaceutical formulation according to claim 1 , where one or more acid-insoluble polymers are selected from the group comprising
acrylate-methacrylic acid copolymers, carboxyalkylcelluloses, cellulose acetate phthalates, cellulose acetate succinates, cellulose acetate trimelliates,
hydroxyalkylcellulose phthalates, hydroxyalkylcellulose acetate succinates, vinyl acetate phthalates, vinyl acetate succinate; ethylacrylate-methacrylic acid copolymer, methyl methacrylate-methacrylic acid copolymer, methyl methacrylate-methyl acrylate-methacrylic acid copolymer, carboxymethylcellulose, cellulose acetate phthalate;
hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, shellac and mixtures thereof.
13 . Solid pharmaceutical formulation according to claim 1 , where one or more alkali-insoluble polymers are selected from the group comprising acrylate-methacrylate copolymers, basic natural polysaccharides, dimethylaminoethyl methacrylate-methyl methacrylate-butyl methacrylate terpolymer, chitosan and mixtures thereof.
14 . Solid pharmaceutical formulation according to claim 1 , where the core is loaded with up to 90% w/w, based on the mass of the core formulation, of an active ingredient having strong pH-dependent water solubility.
15 . Solid pharmaceutical formulation according to claim 1 , where the core is loaded with up to 60% w/w, based on the mass of the core formulation, of an active ingredient having strong pH-dependent water solubility.
16 . Solid pharmaceutical formulation according to claim 1 , where the core is loaded with piperazineurea.
17 . Solid pharmaceutical formulation according to claim 1 , where the osmagent in the core is selected from the group comprising water-soluble ionic substances, water-soluble nonionic substances, hydrophilic polymers and mixtures thereof.
18 . Solid pharmaceutical formulation according to claim 1 , where the osmagent in the core is selected from the group comprising magnesium chloride, magnesium sulphate, lithium chloride, sodium chloride, potassium chloride, lithium sulphate, sodium sulphate, potassium sulphate, lithium phosphate, sodium phosphate, potassium phosphate, ammonium chloride, ammonium sulphate, ammonium phosphate, sucrose, mannitol, lactose, dextrose, sorbitol, hydroxypropylmethylcellulose, hydroxypropylcellulose, xanthan gum, alginate, sodium carboxylmethylcellulose, polyvinylpyrrolidone, Cl-polyvinylpyrrolidone, polyethylene oxide, carbopols, polyacrylamides, gum arabic and mixtures thereof.
19 . Solid pharmaceutical formulation according to claim 1 , which is a matrix pellet.
20 . Solid pharmaceutical formulation according to claim 1 , where the core has a diameter of from 0.8 mm to 1.25 mm.